



PlatiCept[®]

50 mg Powder, Cisplatin

Effective and flexible
tumor treatment using
locoregional application


EFFECTIVE TUMOR THERAPY IN CHEMOEMBOLIZATION

Platin is effectively combined with ...



Degradable Starch Microspheres (DSM)

Experimental data confirm a significantly increased accumulation of platin in tumor tissue in combination with DSM¹



Comparison of carboplatin concentration in healthy liver, healthy kidney, and liver tumor after i.a. carboplatin and i.a. coapplication of carboplatin and DSM in VX-2 liver tumor-bearing rabbits¹

■ Liver
■ Kidney
■ Tumor



Cytostatics

Cisplatin can be successfully used in combination with anthracyclines^{2,3,4}



Radiation therapy

Cisplatin is a well-established chemotherapeutic drug and simultaneously well-known radiosensitizer^{5,6}

Advantages of Cisplatin over Doxorubicin in TACE

- **Significant faster tumor response in TACE** compared to Doxorubicin⁷
- **Significant prolongation of progression-free survival** compared to Doxorubicin⁸
- **Significant prolonged overall survival** compared to Doxorubicin⁹⁻¹¹
- **Tumor response in anthracycline refractory patients**^{7,12}

AUC Area under curve in targeted tumor tissue
TACE Transarterial chemoembolization

FLEXIBLE USE FOR TACE & TPCE

Cisplatin is proven as palliative locoregional therapy in the following types of tumors



Liver

- Hepatocellular carcinoma (HCC)⁷⁻¹²
- Intrahepatic cholangiocarcinoma (ICC)^{3,4,13}
- Liver metastases (e.g. CRC)¹⁴




Lung

- Primary lung cancer^{15,16}
- Lung metastases^{15,16}

Meeting the needs of locoregional application

Conventional
ready-to-use solution
**Fix pre-determined
concentration**



PlatiCept[®]
lyophilized powder
**Allows reduced volumes
for TACE & TPCE¹⁷**

Advantages

Flexible volumes
High concentration
Fast administration

TPCE Transpulmonary chemoembolization
CRC Colorectal cancer

 **PlatiCept[®]**
50 mg Powder, Cisplatin



PlatiCept® is approved in Spain and Germany.
PZN: 14169257

PlatiCept®: Unique lyophilized Cisplatin

- Second most commonly used chemotherapeutic agent in intra-arterial application¹⁹
- The only available Cisplatin powder in Europe

Ordering Information

For information on ordering please contact your local distributor or PharmaCept:
info@pharmacept.com

References

- Pohlen U et al. (2000): Increased carboplatin concentration in liver tumors through temporary flow retardation with starch microspheres (Spherex) and gelatin powder (Gelfoam): An experimental study in liver tumor-bearing rabbits. *Journal of Surgical Research* 92: 165–170; (concerns Spherex®)
- Ma MC et al. (2014): Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma. *The Scientific World Journal* 2014, Article ID 160138
- Goerg F et al. (2019): Chemoembolization with Degradable Starch Microspheres for Treatment of Patients with Primary or Recurrent Unresectable, Locally Advanced Intrahepatic Cholangiocarcinoma: A Pilot Study. *Cardiovasc Intervent Radiol* 42(12): 1709–1717; (concerns EmboCept® S)
- Kirchhoff T et al. (2005): Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. *World J Gastroenterol* 11(8): 1091–1095; (concerns Spherex®)
- Berlo D van et al. (2019): Micro cone beam computed tomography for sensitive assessment of radiation-induced late lung toxicity in preclinical models. *Radiother Oncol* 138: 17–24
- Iwata H et al. (2020): Combined effects of cisplatin and photon or proton irradiation in cultured cells: radiosensitization, patterns of cell death and cell cycle distribution. *J Radiat Res* 61(6): 832–841
- Maeda N et al. (2012): Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion. *Cardiovasc. Intervent Radiol* 35(1), 82–89; (concerns Lipiodol®)
- Kasai K et al. (2013): Therapeutic efficacy of transarterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. *World J Gastroenterol* 19(14), 2242–2248; (concerns Lipiodol®)
- Kasai K et al. (2010): Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. *World J Gastroenterol* 16(27), 3437–3444; (concerns Lipiodol®)
- Ono Y et al. (2000): Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. *Am J Clin Oncol* 23(6), 564–568; (concerns Lipiodol®)
- Kamada K et al. (2001): Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. *J Vasc Interv Radiol* 12(7), 847–854; (concerns Lipiodol®)
- Seki A et al. (2012): Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma. *Cardiovasc Intervent Radiol* 35: 555–562; (concerns HepaSphere™)
- Schicho A et al. (2017): Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC): Results from a National Multi-Center Study on Safety and Efficacy. *Med Sci Monit* 23: 796–800; (concerns EmboCept® S)
- Nishiofuku H et al. (2013): Transcatheter Arterial Chemoembolization Using Cisplatin Powder Mixed with Degradable Starch Microspheres for Colorectal Liver Metastases after FOLFOX Failure: Results of a Phase I/II Study. *J Vasc Interv Radiol* 24: 56–65
- PlatiCept® SmPC
- Vogel TJ et al. (2016): Feasibility of assessing pulmonary blood volume using C-arm CT during transpulmonary chemoperfusion and chemoembolization in primary and secondary lung tumours. *Br J Radiol* 89(1062): 20150244; (concerns EmboCept® S)
- Internal data

PlatiCept® 50 mg powder for solution for injection. Active ingredient: cisplatin. Qualitative and quantitative composition: 1 vial contains 50 mg of cisplatin. **List of excipients:** Mannitol(Ph.Eur.) (E 421), Sodium chloride, Hydrochloric acid 0,36 %. This medicinal product contains 177 mg (7.7 mmol) of sodium per vial, which must be considered when treating patients with low-sodium diets. **Therapeutic indications:** Metastatic testicular and ovarian tumours, Advanced bladder cancer, Squamous cell carcinoma of the head and neck, Lung carcinoma (small cell and non-small cell). **Contraindications:** Cisplatin is contraindicated in: Hypersensitivity to the active ingredient or to any of the excipients. Patients with renal impairment. Patients with dehydration. Patients with myelosuppression. Patients with hearing impairment. Patients with cisplatin-induced neuropathy. Patients who breastfeeding. In combination with attenuated vaccines, including the yellow fever vaccine. Start of new anticonvulsant treatment with phenytoin. **Undesirable effects:** Very common: Bone marrow failure, thrombocytopenia, leukopenia, anaemia, hyponatraemia, ototoxicity, vomiting, nausea, anorexia, diarrhoea, acute renal failure, renal tubular disorders. Common: sepsis, neurotoxicity, deafness and vestibular toxicity combined with vertigo, arrhythmia, bradycardia, tachycardia, phlebitis, dyspnoea, pneumonia, respiratory failure, hepatic dysfunction with elevated serum levels of transaminase and bilirubin which is reversible, erythema, skin ulcers, localised oedema, pain. Uncommon: anaphylactic reaction, rash, urticaria, erythema or pruritus, fever, hypomagnesaemia, metallic colouration of the gums, alopecia, dysfunctional spermatogenesis and ovulation, painful gynecostasia. Rare: acute leukaemia, anaphylactic reactions, immunosuppression, inappropriate antidiuretic hormone secretion syndrome, Hypercholesterolaemia, hypocalcaemia, hypokalaemia, hypophosphataemia, tetany, Convulsion, peripheral neuropathy, leukoencephalopathy, reversible posterior leukoencephalopathy syndrome, Optic neuritis, eye movement disorder, papilloedema and cortical blindness, blurred vision and altered colour perception, Inability to hold a normal conversation, myocardial infarction, hypertension, severe coronary artery disease, hyperfension, stomatitis, decreased levels of serum albumin. Very rare: inappropriate antidiuretic hormone secretion, elevated iron concentrations, seizures, cardiac arrest, cerebral or coronary ischaemia, impaired peripheral circulation associated with Raynaud's syndrome. Not known: infections, coombs-positive haemolytic anaemia, increased blood amylase, dehydration, hyperuricaemia, cerebrovascular accident, haemorrhagic stroke, ischaemic stroke, ageusia, cerebral arteritis, Lhermitte's sign, myelopathy, autonomic neuropathy, retinal pigmentation, tinnitus, cardiac disorder, thrombotic microangiopathy (haemolytic uraemic syndrome), pulmonary embolism, hiccups, skin rash, alopecia, muscle spasms, pyrexia (very common), asthenia, malaise, extravasation at the injection site. **Warnings:** Keep out of the sight and reach of children. For further warnings, precautions and interaction with other medical products see SmPC. **Prescription only. PharmaCept GmbH, Bessemerstr. 82, 12103 Berlin, Germany.**
Date of revision of the text: October 2018

PharmaCept GmbH, Bessemerstr. 82, 12103 Berlin, Germany

Phone: +49-(0)30-7565985-0, Fax: +49-(0)30-7565985-11, info@pharmacept.com

PlatiCept® is a registered trademark of PharmaCept GmbH.

© 2021 PharmaCept GmbH, Berlin, Germany.

Art.-Nr. 202011007-12/2020